Canadian researchers have identified a type of endometrial cancer—a uterine papillary serous carcinoma (UPSC)—that is resistant to radiotherapy.
Canadian researchers have identified a type of endometrial cancer-a uterine papillary serous carcinoma (UPSC)-that is resistant to radiotherapy.
They analyzed the medical records of 62 women with biopsy-proven endometrial cancer of at least stage II who were treated with radiotherapy followed by hysterectomy. They looked at variables such as patient characteristics, tumor stage, histologic grade and subtype, and radiation technique and dose to determine if any were associated with the complete pathologic response to treatment that occurred in 24 of the women.
It turned out that the only variable predictive of response to treatment was whether the cancer was a UPSC; none of the seven women with a UPSC responded well to radiotherapy, even though they were comparable to the other women in all other regards.
Daré Bioscience initiates phase 3 clinical trial for ovaprene contraceptive
December 5th 2023Daré Bioscience has commenced a pivotal phase 3 clinical trial for ovaprene, an intravaginal contraceptive that releases a locally acting agent to prevent sperm entry into the cervical canal, marking a significant step towards a non-hormonal contraceptive option for women.
Read More
Exploring menstrual health: Insights from the Avon longitudinal study
December 5th 2023Unveiling a comprehensive analysis of menstrual cycle characteristics in mothers and daughters, this article delves into the diverse features, potential risk factors, and the importance of understanding these nuances for effective menstrual health management.
Read More
Integrating pharmacists into PPHTN management for enhanced blood pressure control
December 4th 2023A study reveals that involving pharmacists in the care of postpartum women at risk of persistently elevated blood pressure, as presented at the American Society of Health-System Pharmacists 2023 Midyear Clinical Meeting and Exhibition, can provide an effective and feasible solution to managing hypertensive disorders, reducing postpartum readmission risks, and improving overall health care access.
Read More